Lexology December 23, 2019
Despite trade wars and economic shifts in China and the European Union, early-stage investing in life sciences, particularly in the biotechnology and medical device sectors, remains strong and presents myriad opportunities for the prepared.
Significant funding continues to roll into the life sciences sector, driven by legacy venture capital (VC) funds bringing in new money, new players that are outraising their fund targets, and active corporate venture capital players.
The confluence of funding and an innovation-friendly regulatory environment provide early-stage life sciences companies with ample opportunity to bring their solutions to market. There are a number of factors driving opportunity in this space, and genuine opportunities for companies to position themselves as attractive partners.
GETTING INNOVATION TO MARKET AND SUBSECTORS...
Today's Sponsors
Today's Sponsor